TheraRadar
Data updated: May 26, 2026

ADZENYS ER (amphetamine)

CNS Approved 2017-09-15
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Discontinued
First Approved
2017-09-15
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SUSPENSION, EXTENDED RELEASE

Companies

Active Ingredient: AMPHETAMINE

ADZENYS ER Approval History

2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2017 to 2022
Feb 2022 SUPPL
Label · Labeling
Sep 2017 ORIGINAL
New Form · Type 3 - New Dosage Form

What ADZENYS ER Treats

1 FDA approvals

Originally approved for its first indication in 2017 .

  • Other (1)
📋

Clinical Trial Registry

4 trials
Trial Sponsor ID Phase Status Title
NCT03242772 results posted Pro00085179 1P50HD093074-01 Ph 2 terminated Impact of Combined Medication and Behavioral Treatment for ASD & ADHD
NCT02959892 results posted TAK-041-1002 U1111-1184-1947, 2016-002346-23 Ph 1 completed A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
NCT02020408 results posted 090661 R01MH092793 Ph 4 completed Monoamine Contributions to Neurocircuitry in Eating Disorders
NCT00733993 results posted DA09262 P50DA009262, DPMCDA Ph 1, Ph 2 completed Caffeine and Cocaine
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ADZENYS ER FDA Label Details

View full patent landscape →
3 OB patents · 1 families · 20 international docs across 3 countries

ADZENYS ER Patents & Exclusivity

Latest Patent: Jun 2032

Patents (3 active)

US8709491 Expires Jun 28, 2032
US9017731 Expires Jun 28, 2032
US9265737 Expires Jun 28, 2032
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ADZENYS ER

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2032
  • 3 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.